ClinVar

Description

The CHEK2 c.1427C>T variant is predicted to result in the amino acid substitution p.Thr476Met. This variant has been reported in multiple individuals with breast cancer, with a recent study reporting an odds ratio of 1.35 (95% CI=1.03-1.77, P-value=0.03) (Table S1, Le Calvez-Kelm et al. 2011. PubMed ID: 21244692; Desrichard et al. 2011. PubMed ID: 22114986; Roeb et al. 2012. PubMed ID: 22419737; Angelova et al. 2012. PubMed ID: 22862163; Table S1, Susswein et al. 2016. PubMed ID: 26681312; Schubert et al. 2019. PubMed ID: 30426508; Lerner-Ellis et al. 2020. PubMed ID: 31784482; Figure 2, Bychkovsky et al. 2022. PubMed ID: 36136322). This variant has also been reported in individuals with ovarian cancer, prostate cancer, pancreatic cancer, and colorectal cancer (Table S1, Hu et al. 2016. PubMed ID: 26483394; Table S1, Susswein et al. 2016. PubMed ID: 26681312; Table 1, Isaacsson Velho et al. 2018. PubMed ID: 29368341; Table 1, Young et al. 2018. PubMed ID: 29945567; Table S4, Bertelsen et al. 2019. PubMed ID: 31263571; Table S3, Arvai et al. 2019. PubMed ID: 31341520). In vitro and in vivo experimental studies suggest this variant results in reduced or absent kinase activity and DNA damage response (Desrichard et al. 2011. PubMed ID: 22114986; Table 1, Roeb et al. 2012. PubMed ID: 22419737; Figure 1, Kleiblova et al. 2019. PubMed ID: 31050813). An additional functional study using protein expression in yeast found that his variant results in semi-functional kinase activity (Delimitsou et al. 2019. PubMed ID: 30851065). In the gnomAD public population database this variant has been reported in up to ~0.05% of alleles in a subpopulation and has conflicting interpretations of uncertain, risk allele, and likely pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/128060/). Taken together, we interpret c.1427C>T (p.Thr476Met) as likely pathogenic.